摘要
目的探讨克唑替尼和化疗在治疗间变性淋巴瘤激酶(ALK)阳性晚期非小细胞肺癌(NSCLC)患者中的临床疗效。方法选取2014年4月至2015年10月间内蒙古医科大学附属医院收治的50例NSCLC患者的临床资料,采用随机数字表法分为观察组与对照组,每组25例。观察组患者采用克唑替尼治疗,对照组患者采用多西他赛治疗。比较两组患者的临床疗效、生存质量、生存情况及不良反应。结果治疗后,观察组患者的临床疗效和卡氏(KPS)生存质量情况明显较对照组好,差异均有统计学意义(均P<0.01)。治疗前,两组患者的进展生存期(PFS)及总生存期(OS)评分比较,差异无统计学意义(P>0.05)。治疗后,观察组患者的PFS及OS评分均高于对照组,且两组患者的PFS及OS评分均较同组治疗前高,差异均有统计学意义(均P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论与常规化疗法相比,克唑替尼治疗ALK阳性晚期NSCLC患者疗效更佳,可延长患者的PFS及OS,提升患者生活质量,值得推广。
Objective To compare and analyze the clinical effecacy of crizotinib versus chemotherapy in treating patients with ALK positive non-small cell lung cancer（ NSCLC）. Methods Clinical data of 50 NSCLS patients treated at The Affiliated Hospital of Inner Mongolia Medical University from April2014 to October 2015 was retrospectively analyzed. Using a random number table,patients were divided into an observation group（ crizotinib,25 patients） and a control group（ docetaxel,25 patients）. Information at baseline,clinical efficacy,quality of life,survival situation and the incidence of adverse reactions were compared between the two groups. Results After treatment,the clinical efficacy,Karnofsky performance status（ KPS） and quality of life in the observation group were better than in the control group（ all P〈0. 01）. Before treatment,there was no statistical difference in progression-free survival（ PFS） and overall surval（ P〉0. 05）. After treatment,PFS and OS score was higher in the observation group than in the control group（ all P〈0. 05） and were obviously better than those before the treatment（ P〈0. 05）. There was no statistical difference in the adverse effects between the two groups（ P〉0. 05）. Conclusion Compared with routine chemotherapy,crizotinib showed better clinical efficacy in extending PFS and OS and improving the quality of life. It＇s worth promoting.
作者
乌日罕
苏乌云
WU Ri-han SU Wu-yun(Department of Medical Oncology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 01005, China)
出处
《中国肿瘤临床与康复》
2017年第4期404-407,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
